Risk of Malignancy in Spondyloarthritis: A Systematic Review.

Authors :: Karmacharya P
Shahukhal R
Ogdie A
Source :: Rheumatic diseases clinics of North America [Rheum Dis Clin North Am] 2020 Aug; Vol. 46 (3), pp. 463-511. Date of Electronic Publication: 2020 Jun 11.
Publication Year :: 2020
Abstract: Systematic inflammatory diseases, including rheumatoid arthritis (RA), are associated with an increased risk of malignancies. However, the pathogenesis of spondyloarthritis (SpA), which includes both ankylosing spondylitis and psoriatic arthritis, is different from RA, and the risk of malignancy and sites involved may also be different. It is important to better understand associations of SpA with site-specific cancers to facilitate appropriate cancer screening. The goal of this review was to examine the association of SpA with malignancy and the potential impact of therapy for SpA on development of malignancy.<br />Competing Interests: Disclosure A. Ogdie has served as a consultant for AbbVie, Amgen, BMS, Celgene, Corrona, Janssen, Lilly, Novartis, and Pfizer and has received grants from Novartis and Pfizer to Penn and from Amgen to Forward.<br /> (Copyright © 2020 Elsevier Inc. All rights reserved.)